Syndax Pharmaceuticals (SNDX) Tops Q4 EPS by 3c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.62), $0.03 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $0 versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c
• Bit Digital (BTBT) Misses Q2 EPS by 27c